44 related articles for article (PubMed ID: 38655602)
1. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
[TBL] [Abstract][Full Text] [Related]
2. Discovery of LHQ490 as a highly selective fibroblast growth factor receptor 2 (FGFR2) inhibitor.
Li H; Ke R; Zhou Y; Chang S; Wang J; Su C; Wu P; Yang B; Wang Z; Ding K; Ma D
Eur J Med Chem; 2024 Jun; 272():116473. PubMed ID: 38718625
[TBL] [Abstract][Full Text] [Related]
3. Discovery of potent small molecule ubiquitin-specific protease 10 inhibitors with anti-hepatocellular carcinoma activity through regulating YAP expression.
Lu Y; Gao J; Wang P; Chen H; He X; Luo M; Guo Y; Li L; Zhuang W; Zhang B; Lin N; Li J; Zhou Y; Dong X; Che J
Eur J Med Chem; 2024 Jun; 272():116468. PubMed ID: 38718626
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects.
Lu X; Chen H; Patterson AV; Smaill JB; Ding K
J Med Chem; 2019 Mar; 62(6):2905-2915. PubMed ID: 30403487
[TBL] [Abstract][Full Text] [Related]
5. FGF19-
Raja A; Park I; Haq F; Ahn SM
Cells; 2019 Jun; 8(6):. PubMed ID: 31167419
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel FGFR4 inhibitors through a build-up fragment strategy.
Kim J; Im CG; Oh K; Lee JM; Al-Rubaye F; Min KH
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2343350. PubMed ID: 38655602
[TBL] [Abstract][Full Text] [Related]
7. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway.
Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T
Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of quinazoline derivatives as potent and selective FGFR4 inhibitors.
Pan C; Nie W; Wang J; Du J; Pan Z; Gao J; Lu Y; Che J; Zhu H; Dai H; Chen B; He Q; Dong X
Eur J Med Chem; 2021 Dec; 225():113794. PubMed ID: 34488024
[TBL] [Abstract][Full Text] [Related]
10. Pyrrolo[2,3-b]pyridine-3-one derivatives as novel fibroblast growth factor receptor 4 inhibitors for the treatment of hepatocellular carcinoma.
Jin Q; Zhang D; Gao M; Jiang C; Zhang J
Bioorg Med Chem; 2021 Jan; 29():115862. PubMed ID: 33218898
[TBL] [Abstract][Full Text] [Related]
11. 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors.
Li X; Guise CP; Taghipouran R; Yosaatmadja Y; Ashoorzadeh A; Paik WK; Squire CJ; Jiang S; Luo J; Xu Y; Tu ZC; Lu X; Ren X; Patterson AV; Smaill JB; Ding K
Eur J Med Chem; 2017 Jul; 135():531-543. PubMed ID: 28521156
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on the Underlying Etiology of HCC and Its Effects on Treatment Outcomes.
Ito T; Nguyen MH
J Hepatocell Carcinoma; 2023; 10():413-428. PubMed ID: 36926055
[TBL] [Abstract][Full Text] [Related]
13. A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors.
Chan SL; Schuler M; Kang YK; Yen CJ; Edeline J; Choo SP; Lin CC; Okusaka T; Weiss KH; Macarulla T; Cattan S; Blanc JF; Lee KH; Maur M; Pant S; Kudo M; Assenat E; Zhu AX; Yau T; Lim HY; Bruix J; Geier A; Guillén-Ponce C; Fasolo A; Finn RS; Fan J; Vogel A; Qin S; Riester M; Katsanou V; Chaudhari M; Kakizume T; Gu Y; Porta DG; Myers A; Delord JP
J Exp Clin Cancer Res; 2022 Jun; 41(1):189. PubMed ID: 35655320
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 1,6-Naphthyridin-2(1
Zhang X; Wang Y; Ji J; Si D; Bao X; Yu Z; Zhu Y; Zhao L; Li W; Liu J
J Med Chem; 2022 Jun; 65(11):7595-7618. PubMed ID: 35635004
[TBL] [Abstract][Full Text] [Related]
15. Cancer statistics, 2022.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2022 Jan; 72(1):7-33. PubMed ID: 35020204
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]